Clinical Trial Program of a Medical Instrument Product (SEEDS)

NCT01157455 Phase 4 UNKNOWN

This is a prospective, multi-center registry to evaluate safety and effectiveness of the Everolimus Drug Eluting Stent for treatment coronary revascularization in Chinese patients with long lesion, small vessel or multi-vessel diseases.

Details

Lead sponsor	CCRF Consulting Co., Ltd.
Phase	Phase 4
Status	UNKNOWN
Enrolment	1900
Start date	2010-05
Completion	2013-06

Conditions

• Coronary Artery Diseases

Interventions

• Everolimus Drug Eluting Stent
• Aspirin
• Clopidogrel
• Heparin or Bivalirudin

Primary outcomes

• TVF — 12 months post-index procedure.
  Ischemia-driven Target Vessel Failure (TVF) which is a composite of cardiac death, myocardial infarction (Q and non-Q wave) and target vessel revascularization (TVR),12 months post-index procedure.

Countries

China